Salix Pharmaceuticals Releases Findings from First Colonoscopy Awareness SurveyLAVAL, QC / ACCESSWIRE / March 5, 2024 / Bausch Health Companies...
• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans•...
Conference Call and Webcast Scheduled for March 14, 2024 at 2:00 p.m. PT/5:00 p.m. ETSOUTH SAN FRANCISCO, Calif., March 05,...
Dr. Roizen to provide expertise on longevity and aging Research on aging involving Telomir’s lead product candidate focused on reversing age-related...
BELTSVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...
Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive,...
NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a...
Patients with Alzheimer’s Disease show improvement in brainwaves following 4 weeks of XPro™ therapy. Boca Raton, Florida, March 05, 2024...
TNX-1500, a third generation anti-CD40L mAb, was Fc-modified to preserve the activity and bioavailability of first generation mAbs while addressing...
Vancouver, British Columbia--(Newsfile Corp. - March 5, 2024) - CloudMD Software & Services Inc. (TSXV: DOC) (OTCQX: DOCRF) (FSE: 6PH)...
STOCKHOLM, SWEDEN / ACCESSWIRE / March 5, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
Directed at individuals who may be at risk of elevated PFAS exposure, the new test detects and measures PFAS identified...
SEATTLE, WA / ACCESSWIRE / March 4, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that...
NEW YORK and LONDON, March 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp, specializing in state-of-the-art image enhancement and precision...
Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first FDA-approved treatment for...
AGOURA HILLS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) invites participation in our STOP-PC clinical trial...
Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer; Unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in on-going phase...
WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, announces the formation...
Ethics and regulatory approvals finalized for world-first take-home use of a psychedelic medicine MB22001 in placebo-controlled trial in depressed patients...
Vancouver, British Columbia--(Newsfile Corp. - March 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...